Omicron: A Heavily Mutated SARS-CoV-2 Variant Exhibits Stronger Binding to ACE2 and Potently Escapes Approved COVID-19 Therapeutic Antibodies

Abstract excerpt

The new SARS-CoV-2 variant of concern “Omicron” was recently spotted in South Africa and spread quickly around the world due to its enhanced transmissibility. The variant became conspicuous as it harbors more than 30 mutations in the Spike protein with 15 mutations in the receptor-binding domain (RBD) alone, potentially dampening the potency of therapeutic antibodies and enhancing the ACE2 binding. More worrying,...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Bacillus and Francisella bacterial research
• Share to Monoclonal and Polyclonal Antibodies Research
• Share to SARS-CoV-2 and COVID-19 Research